Caveolin-1 regulates cancer.pdf (9.74 MB)

Caveolin-1 regulates cancer cell metabolism via scavenging Nrf2 and suppressing MnSOD-driven glycolysis.

Download (9.74 MB)
journal contribution
posted on 03.08.2016, 00:00 by PC Hart, BA Ratti, M Mao, Kristine Ansenberger-Fricano, AN Shajahan-Haq, AL Tyner, RD Minshall, MG Bonini
Aerobic glycolysis is an indispensable component of aggressive cancer cell metabolism. It also distinguishes cancer cells from most healthy cell types in the body. Particularly for this reason, targeting the metabolism to improve treatment outcomes has long been perceived as a potentially valuable strategy. In practice, however, our limited knowledge of why and how metabolic reprogramming occurs has prevented progress towards therapeutic interventions that exploit the metabolic peculiarities of tumors. We recently described that in breast cancer, MnSOD upregulation is both necessary and sufficient to activate glycolysis. Here, we focused on determining the molecular mechanisms of MnSOD upregulation. We found that Caveolin-1 (Cav-1) is a central component of this mechanism due to its suppressive effects of NF-E2-related factor 2 (Nrf2), a transcription factor upstream of MnSOD. In transformed MCF10A(Er/Src) cells, Cav-1 loss preceded the activation of Nrf2 and its induction of MnSOD expression. Consistently, with previous observations, MnSOD expression secondary to Nrf2 activation led to an increase in the glycolytic rate dependent on mtH2O2 production and the activation of AMPK. Moreover, rescue of Cav-1 expression in a breast cancer cell line (MCF7) suppressed Nrf2 and reduced MnSOD expression. Experimental data were reinforced by epidemiologic nested case-control studies showing that Cav-1 and MnSOD are inversely expressed in cases of invasive ductal carcinoma, with low Cav-1 and high MnSOD expression being associated with lower 5-year survival rates and molecular subtypes with poorest prognosis.

Funding

We would like to acknowledge funding from the U.S. Department of Defense, ARO #61758-LS to M.G.B., UIC/Department of Medicine Innovators Fund/University of Illinois at Chicago to M.G.B.

History

Publisher Statement

This is a copy of an article published in Oncotarget. © 2016 Impact Journals Publications. © The Author(s).www.impactjournals.com/oncotarget 308 Oncotarget www.impactjournals.com/oncotarget/

Publisher

Impact Journals

Language

en_US

Issue date

05/01/2016

Exports

Categories

Exports